Treatment duration depends on individual weight loss goals, metabolic response, and how well lifestyle changes have been established
To date, the SURPASS program includes nine ongoing randomized controlled trials in patients with type2 diabetes: SURPASS 1 in monotherapy, SURPASS 2 versus semaglutide, SURPASS 3 versus degludec, SURPASS 4 versus glargine and established CV disease, SURPSS 5 basal insulin add-on, SURPASS AP- Combo versus glargine, and SURPASS-CVOT
For researchers running long protocols, the savings justify the upgrade
[DOI] [PMC free article] [PubMed] [Google Scholar] 74.Scheerer P., Borchert A., Krauss N., Wessner H., Gerth C., Hhne W., Kuhn H
:112 Creta M, Arcaniolo D, Celentano G, Napolitano L, La Rocca R, Capece M et al (2021) Toxicity of antioxidant supplements in patients with male factor infertility: a systematic review and meta-analysis of randomized controlled trials